This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Celgene Corporation, and Jazz Pharmaceuticals.

Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Andrew Artz, MS, MD
University of Chicago Medicine

Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
University of Chicago Medicine

Take a deep dive into the updated WHO criteria for diagnosing myeloid malignancies, the mechanisms of action of new novel therapies, and the growing role of molecular mutations, while also learning how to take a collaborative, multidisciplinary approach to classifying these diseases. Advanced practitioners are key to managing the evolving continuum of myeloid malignancies and creating a multidisciplinary team approach to managing patients with complex myeloid malignancies.



 

Download Transcript

 
 

Download Slides

 

 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.